

Resource Summary Report

Generated by [kravitz2](#) on Jul 30, 2026

PerCP/Cyanine5.5 anti-mouse CD45

RRID:AB_893340

Type: Antibody

Proper Citation

BioLegend Cat# 103132, RRID:AB_893340

Antibody Information

URL: http://antibodyregistry.org/AB_893340

Proper Citation: BioLegend Cat# 103132, RRID:AB_893340

Target Antigen: CD45

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PerCP/Cyanine5.5 anti-mouse CD45

Description: This monoclonal targets CD45

Target Organism: mouse

Clone ID: Clone 30-F11

Antibody ID: AB_893340

Vendor: BioLegend

Catalog Number: 103132

Alternative Catalog Numbers: 103131

Record Creation Time: 20250819T235027+0000

Record Last Update: 20250820T063457+0000

Ratings and Alerts

No rating or validation information has been found for PerCP/Cyanine5.5 anti-mouse CD45.

No alerts have been found for PerCP/Cyanine5.5 anti-mouse CD45.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 115 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Zitti B, et al. (2026) Positioning and reversible suppression of CCR7+ dendritic cells in perivascular tumor niches shape cancer immunity. *Immunity*, 59(1), 161.

Khan F, et al. (2026) Microglial TBK1 Signaling Promotes Breast Cancer Brain Metastasis. *Cancer research*, 86(1), 12.

Wang G, et al. (2025) Distinct adipose progenitor cells emerging with age drive active adipogenesis. *Science (New York, N.Y.)*, 388(6745), eadj0430.

Henriques-Oliveira L, et al. (2025) Anchored screening identifies transcription factor blueprints underlying dendritic cell diversity and subset-specific anti-tumor immunity. *Immunity*.

Wang S, et al. (2025) ENPP1 inhibitor with ultralong drug-target residence time as an innate immune checkpoint blockade cancer therapy. *Cell reports. Medicine*, 6(9), 102336.

Gianì F, et al. (2025) Vascular protection by young circulating extracellular vesicles ameliorates aging-related pulmonary fibrosis. *American journal of physiology. Cell physiology*, 329(1), C159.

Cramer GM, et al. (2025) PD-1 Blockade Mitigates Surgery-Induced Immunosuppression and Increases the Efficacy of Photodynamic Therapy for Pleural Mesothelioma. *Cancer research communications*, 5(5), 841.

Han S, et al. (2025) USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment. *Cancer immunology research*, 13(8), 1226.

Gawish R, et al. (2025) Filamin A editing in myeloid cells reduces intestinal inflammation and protects from colitis. *The Journal of experimental medicine*, 222(9).

Huang L, et al. (2025) Interferon-driven CAF reprogramming augments immunogenic response to neoadjuvant radiotherapy in colorectal cancer. *Cell reports. Medicine*, 6(8), 102251.

Webb L, et al. (2025) Membrane-bound IL-15 co-expression powers a potent and persistent CD70-targeted TRuC T-cell therapy. *Frontiers in immunology*, 16, 1609658.

Song H, et al. (2025) Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy. *Cancer cell*, 43(3), 503.

Rodella A, et al. (2025) Oncostatin M is dispensable for the regulation of hematopoietic stem/progenitor cell traffic by neutrophils. *iScience*, 28(6), 112646.

Xu Y, et al. (2025) Type I interferon signaling controls the early hematopoietic expansion in response to β -glucan. *iScience*, 28(5), 112347.

Kim SH, et al. (2025) IL-10 sensing by lung interstitial macrophages prevents bacterial dysbiosis-driven pulmonary inflammation and maintains immune homeostasis. *Immunity*, 58(5), 1306.

Zhang Z, et al. (2025) Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging. *Cell reports. Medicine*, 6(7), 102209.

Kulig P, et al. (2025) Efficacy of IDOR-1117-2520, a novel, orally available CCR6 antagonist in preclinical models of skin dermatitis. *British journal of pharmacology*, 182(15), 3452.

Matsuda Y, et al. (2025) Adrenomedullin-RAMP2 System Modulates Inflammation and Tissue Repair in Experimental Autoimmune Uveitis Via T-Cell and M2 Macrophage Regulation. *Investigative ophthalmology & visual science*, 66(6), 12.

Fouque A, et al. (2025) Constructing chimeric mouse islets to study alpha- and delta-cell influence on beta-cell feature. *Molecular metabolism*, 101, 102245.

Ali H, et al. (2025) Neuropeptide adrenomedullin remodels stemness and macrophage dynamics in glioblastoma. *Cell reports*, 44(10), 116342.